基本信息
views: 522
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology, chemistry, and medicine.
Carr and his group of staff scientists and postdoctoral fellows collaborate with scientists throughout the Broad Institute community (comprised of MIT, Harvard University Faculty of Arts and Sciences, Harvard Medical School, and the 17 Harvard-affiliated hospitals) to apply state-of-the-art proteomics technology to address compelling questions in biology, chemistry, and clinical medicine.
Research in his laboratory focuses on developing and applying new technologies to quantify proteins and their modifications and interaction partners in tissues, cells, and biofluids with high sensitivity and specificity; improving informatics for peptide and protein assignment using mass spectrometry (MS) data; and integration of MS-derived data with genomic data to understand disease biology and drug effects. The group also has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer and cardiovascular and infectious diseases, as well as pharmacodynamics markers of drug response.
Carr and his group of staff scientists and postdoctoral fellows collaborate with scientists throughout the Broad Institute community (comprised of MIT, Harvard University Faculty of Arts and Sciences, Harvard Medical School, and the 17 Harvard-affiliated hospitals) to apply state-of-the-art proteomics technology to address compelling questions in biology, chemistry, and clinical medicine.
Research in his laboratory focuses on developing and applying new technologies to quantify proteins and their modifications and interaction partners in tissues, cells, and biofluids with high sensitivity and specificity; improving informatics for peptide and protein assignment using mass spectrometry (MS) data; and integration of MS-derived data with genomic data to understand disease biology and drug effects. The group also has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer and cardiovascular and infectious diseases, as well as pharmacodynamics markers of drug response.
Research Interests
Papers共 363 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CELL REPORTSno. 1 (2024): 113596-113596
Communications biologyno. 1 (2024): 87-87
crossref(2023)
Mariska Simpson,Heidi De Luca, Sarah Cauthorn,Phi Luong,Namrata Udeshi,Tanya Svinkina, Stefanie Schmeider,Steven Carr,Michael Grey,Wayne Lencer
bioRxiv (Cold Spring Harbor Laboratory)no. 12 (2023)
Cited0Views0Bibtex
0
0
Molecular & Cellular Proteomicsno. 6 (2023): 100563-100563
Human molecular geneticsno. 1 (2023): 30-45
Martin Stražar, Jihye Park,Jennifer G Abelin,Hannah B Taylor,Thomas K Pedersen,Damian R Plichta,Eric M Brown,Basak Eraslan, Yuan-Mao Hung,Kayla Ortiz,Karl R Clauser,Steven A Carr,
Molecular & cellular proteomics : MCPno. 12 (2023): 100665-100665
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn